IP strategy for biotech startups

Michael Hostetler, IP Partner at Wilson Sonsini Goodrich & Rosati, discusses how biotech startups should manage their intellectual property. SLIDES HERE: www.baybridgeb...
Mike developed and implemented IP strategy for 5 FDA-approved drugs (Imbruvica, Erleada, Lesinurad, Otiprio and Xiidra) as well as drugs in 50 active clinical trials. He has advised on dozens of M&A transactions including 6 sell-side representations of $1B+ companies, and advises many venture funds on IP matters.
TOPICS COVERED:
1:50 -- Michael's background
4:30 -- Trade secrets
10:55 -- Patents
21:56 -- Basic patentability requirements
48:48 -- Patent strategy for entrepreneurs
1:00:34 -- Creating the perfect provisional patent
1:09:48 -- IP diligence